What Q2 2026 Taught MedTech Leaders
Ten large medtech companies reported the June quarter. Nine raised or held full-year guidance. One cut. The difference was not the environment. It was how long it took the building to hear what the field already knew.
Q2 closed six weeks ago. The earnings calls wrapped two weeks ago. So we can finally talk about what the quarter taught instead of what everybody predicted it would.
Ten large medtech companies reported the June quarter. Nine raised or held full-year guidance. One cut.
Now read the middle of that chart before you read the ends.
Boston Scientific grew 7% organic in Q2. That is faster than ICU Medical, faster than Zimmer Biomet, faster than J&J MedTech and faster than GE HealthCare. All four of those companies raised or reaffirmed. Boston Scientific cut.
So the cut was not about the quarter. The quarter was good.
They beat the organic guide. They beat consensus on sales. They beat the high end of their own EPS range. Then they took the year down.
That is the second cut in five months.
In February the company guided 2026 to 10% to 11% organic growth. In April it moved to 6.5% to 8.0%. On July 29 it landed at 5% to 6%, and guided Q3 to 3% to 5%. The company delivered 15.8% organic growth in 2025. It is now telling you the back half of 2026 runs at about a quarter of that pace.
Here is why this is the most useful thing that happened to our industry all year.
Every company on that first chart operated in the same environment. The same tariff schedule. The same hospital operating margins. The same Medicaid statute. The same Section 232 investigation sitting over the whole sector. Q2 held the macro constant and varied the commercial situation.
That is an experiment nobody designed and everybody should read.
The Mechanic
Lesson one. The macro stopped being an alibi
Go back and look at what we all said in Q1. Tariffs. Capital freezes. The Medicaid cliff. Every one of those was real, and every one of them became the sentence that explained a missed number.
Q2 took the sentence away.
Start with tariffs. Medtronic trimmed its assumed annual tariff impact to roughly $185 million, down from a $200 million to $350 million range. Commerce owed the President its Section 232 report on medical devices at the end of May, which means the deadline came and went inside Q2 with no device tariff in force. And by the June quarter, tariffs had turned into a line item running the other direction. GE HealthCare's Q2 EPS benefited from tariff refunds. Medline had to strip tariff refunds out of its top line to report a clean organic number.
Tariffs went from the thing that was going to break the year to a footnote you back out of the math.
Now the capital freeze.
GE HealthCare books hospital capital orders for a living. In Q2 it posted record organic order growth of 11.1%, against 3.4% in the same quarter last year, with a book-to-bill of 1.15 and a backlog of $23.9 billion. Orders grew in every segment. HCA left its 2026 capital plan at $5.0 to $5.5 billion, unchanged.
Hospitals are genuinely squeezed. Kaufman Hall has operating margins down about 5% year over year through May, with expenses up 5% and expense per adjusted discharge growing faster than net patient revenue. All of that is true. And they still bought.
Then look at what they did instead of freezing.
Eighteen hospital transactions were announced between April and June, against eight in the same window a year earlier. Transacted revenue went from $1.4 billion to $7.7 billion. Three were mega-mergers. Only three of the eighteen involved a financially distressed seller, and two-thirds were independent systems that went looking for a partner while they still had a choice.
We wrote about vendor rationalization in Issue 36, when Sutter and Allina signed their letter of intent. Q2 turned that into a pattern. Every one of those eighteen deals contains a process where two item masters become one and somebody's approved vendor list gets shorter.
A frozen buyer does nothing. These buyers made a list.
The Medicaid cliff moved early too.
Issue 37 framed December 2026 as the trigger date. That was the statute. What actually happened is that Nebraska switched on work-requirement enforcement May 1, inside Q2, as the first state in the country. Montana and Arkansas followed in July. Iowa goes December 1. Everyone else by January 1.
So I was directionally right and calendar-wrong, and the calendar is the part that matters to a rep working a Nebraska account. The date in the law is the deadline. It is not when it starts.
Add all of that up. The environment everybody blamed in Q1 is the same environment in which nine of these ten companies raised or held. The weather was real. The weather was also shared.
Lesson two. You can win the trial and lose the quarter
This is the part of Q2 I cannot stop thinking about.
On March 28, at the American College of Cardiology meeting and simultaneously in the New England Journal of Medicine, Boston Scientific announced that CHAMPION-AF met all primary and secondary endpoints. Watchman FLX against direct oral anticoagulants, first-line, in a broad AFib population. Superior net clinical benefit. A 45% reduction in bleeding risk. One hundred forty-one sites, 99% procedural success. This is the trial that opens left atrial appendage closure to a population the company sizes in the millions.
It is about as good a clinical outcome as a device company gets.
Watchman then grew 4% in the quarter. In 2025 it grew about 30%.
The company's own explanation is worth reading slowly. The LAAC market slowed, they said, driven primarily by compounding clinical evidence impacting referral patterns.
Compounding clinical evidence. Not competition. Not price. Not reimbursement.
What happened is that CLOSURE-AF, in the same journal in the same year, failed to clear noninferiority against standard care in a different population, one with high stroke risk and high bleeding risk. Two trials. Two populations. Two opposite-looking headlines. And the referring cardiologist, who is not the implanter and has never taken your rep's call, responded the way any careful physician responds to a mixed picture. They got selective. They slowed down. They started asking which patient in front of them is the CHAMPION patient and which one is the CLOSURE patient.
Every one of those pauses is a procedure that does not get scheduled.
Now the commercial lesson, because this is not a cardiology story.
Clinical evidence does not travel to the market through your sales force. It travels through the referral network. Your rep calls on the implanting physician and the service line and the value analysis committee, and that is where the org chart stops. The person who decides whether the patient ever reaches the implanter sits outside your coverage model entirely, has no rep, gets no visit and reads the journal on their own.
When the evidence is one-sided, that gap costs you nothing. Nobody notices. When the evidence gets mixed, the referrer becomes the rate limiter on your entire franchise, and you find out about it in a guidance revision.
This is a Clinical-layer failure that shows up as a Financial-layer number two quarters later. The COF framework exists to catch that before it reaches the number. The question it forces is uncomfortable and simple. Who has to believe this for the procedure to happen, and which of those people do we actually cover?
If the answer includes somebody you have never called on, you do not have a commercial plan. You have a plan for the part of the market that is easy to find.
Lesson three. Penetration is the ceiling nobody puts in the forecast
The other half of Boston Scientific's problem is electrophysiology, and it runs on a different mechanism.
In 2023 Boston Scientific had essentially all of the pulsed field ablation market. By early 2026 it had 41%. Medtronic had 48%. J&J had 11%. Abbott, which launched Volt in January, had already taken about a point.
Three years. Monopoly to four-way fight.
And here is the number that closes the trap. PFA now runs 80% to 85% of all US ablation procedures. The category is full. There is no meaningful pool of radiofrequency conversions left to absorb a share loss, which is exactly what saved everybody's numbers for the previous two years. When the category was filling, you could lose share and still grow, because the category grew faster than you lost. That math is gone.
Mike Mahoney said it plainly on the call. They undercalled the competitive pressures.
Now look at where the damage actually is.
Boston Scientific's electrophysiology business grew 9% globally in Q2. Underneath that, the US grew 3% and international grew 23%. Watchman is the same shape. US up 3%, international up 18%.
Two different franchises, two different root causes, one identical signature. The US is where the category is full and the competition arrived. Everywhere else still has runway. For context, this company's US operational growth was 26% for full-year 2025.
So the strategic question for anyone running a category above roughly 80% penetration is whether your commercial motion has changed to match. Usually it has not.
Adoption selling and displacement selling are different jobs. In adoption you are fighting the status quo, you are looking for the believer, and your evidence job is to publish and present. In displacement you are fighting a competent rep with a similar product and a reference list, you are looking for the quietly dissatisfied, and your evidence job is to answer the trial that was not yours.
Most field organizations in this industry were built, trained, comped and staffed for the first job. Then the category filled up and they got handed the second one, and nobody told them, and nobody changed the comp plan, and the quota went up anyway.
The rep is not underperforming. The rep is doing the job they were trained for in a market that stopped rewarding it.
What actually broke
Put the three lessons together and something uncomfortable falls out.
Our theme all through Q2 was the intelligence gap, and the way we framed it was this. Your buyer is more current than your rep.
Q2's data says something worse.
The field is more current than the forecast.
In February, a company guided its year to 10% to 11%. At that moment a competitor already held 48% of the PFA market. The category was already past 80% penetration. Two contradictory LAAC trials were already in the literature or about to land. Every US rep in an ablation lab could feel the conversation change, and every US rep working a referral base could hear the hesitation.
None of that reached the number until April. Then it needed a second pass in July to reach it fully.
That is not a market failure. Markets do not fail. They just tell you things you did not ask about. What broke is a reporting line that carries quota downward and carries nothing upward.
Most commercial organizations have three or four formal channels for pushing information down to the field, and exactly one for pushing it up, which is the forecast call. And a forecast call is a bad instrument for this, because it asks a rep to convert everything they know into a single number about their own deals. The rep who says "the referring group at Memorial has gone quiet since March and I think it's the CLOSURE paper" has nowhere to put that sentence. It is not a deal. It is not a number. So it dies in the car.
Somebody in that building knew in February. There was no wire.
The Move
This week. Not next quarter.
Score every category you sell on penetration, not on growth rate. Growth rate tells you what happened. Penetration tells you what is available. Anything above 70% is displacement work and should be resourced, coached and comped as displacement work. If you cannot produce a penetration estimate for your top three categories by Friday, that is the finding.
Name the referrer. For your biggest franchise, write down every person who has to act for one procedure to happen, start to finish, beginning before the patient ever meets your implanter. Then mark who owns each name. The unowned rows are your exposure. Do not skip this because it feels like a marketing exercise. Watchman lost two-thirds of its growth rate in an unowned row.
Read the trial that was not yours. Pull the most recent piece of published evidence that cuts against your category, whoever sponsored it. Write ninety seconds of honest answer to it. Not a rebuttal deck. An answer, including who the patient is that the paper is right about. Your competitor's rep is already carrying that paper. Right now the only person in the room who has not read it is you.
Ask a displacement question at your top five accounts. Not "what would it take to bring us in." That is an adoption question and it gets an adoption answer. Ask "what is the one thing about your current setup you have stopped complaining about because you assumed it could not change." Then be quiet.
Map the eighteen. Find out whether any of your top accounts is party to a transaction announced this spring. If it is, get your utilization number relative to contract commitment before the combined item master gets drafted. After the list exists, you are appealing a decision. Before it exists, you are an input.
Leaders, check whether your forecast has an upward channel. Here is the test. When did a piece of field intelligence last change a number in your plan, and can you name the rep it came from? If you cannot name the rep, you do not have a channel. You have a reporting line, and reporting lines only run one way. Build the other direction. It costs one standing question in your existing pipeline review, asked every week, in the same words: what did you hear this week that would change our forecast if it were true?
Then do the hard part, which is following one of those up in front of everybody so the team learns that the answer goes somewhere.
Q1 taught us that the buyer reads more than the rep. Q2 taught us that the rep reads more than the plan.
Nine companies faced the same tariffs, the same hospital margins and the same Medicaid statute, and raised their year. One faced all of it and cut twice. The difference was not the environment. It was how long it took the building to hear what the field already knew.
Somebody on your team knew in February.
Do you have any way for them to tell you?
Dr. Gunter Wessels is the founder of LiquidSMARTS℠, a commercial engineering firm for medical technology companies. LiquidSMARTS℠ guarantees 10% pipeline velocity improvement in 90 days.
Sources: Boston Scientific Q4 2025 (Feb 4, 2026), Q1 2026 (Apr 22, 2026) and Q2 2026 (Jul 29, 2026) results releases, Q2 2026 Financial & Operational Highlights and Q2 2026 earnings call. Abbott, Stryker, Johnson & Johnson, Zimmer Biomet, Intuitive Surgical, GE HealthCare, Merit Medical, ICU Medical and Medline Q2 2026 results, July 2026. Kaufman Hall quarterly hospital M&A report, Q2 2026, and National Hospital Flash Report, May 2026 metrics. KFF Medicaid work-requirement implementation tracker and state Medicaid agency announcements, 2026. CHAMPION-AF: Doshi et al, N Engl J Med 2026;394(21):2083-2094, presented at ACC.26 March 28, 2026. CLOSURE-AF, N Engl J Med 2026. PFA market share analyses, early 2026. HCA Healthcare 2026 capital expenditure guidance. US Department of Commerce Section 232 investigation into medical devices, initiated September 2025.